Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression is asociated with squamous cell carcinoma subtype and high SUV max values in 18F-FDG PET
| Autor: | A. Ruibal Morell, I. Abdulkader-Nallib, V. Pubul Núñez, L. García Bernardo, F. Gude Sampedro, M.C. Pombo Pasín |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pathology
medicine.medical_specialty Lung business.industry Cell General Engineering medicine.disease 030218 nuclear medicine & medical imaging 18f fdg pet 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure medicine General Earth and Planetary Sciences Immunohistochemistry Basal cell Non small cell Stage (cooking) Lung cancer business General Environmental Science |
| Zdroj: | Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 41:28-31 |
| ISSN: | 2253-8089 |
| DOI: | 10.1016/j.remnie.2021.01.001 |
| Popis: | Background To study the possible relation between immunohistochemical expression of vascular endothelial growth factor receptor 1 (VEGFR1) and the maximum standardised uptake value (SUV max) of 18F-FDG PET in patients with non small cell lung cancer (NSCLC). Material and Methods The study included 39 patients with NSCLC (24 squamous cell carcinomas and 15 adenocarcinomas). According to the clinical stage, the patients were distributed as follows: 8 stage I, 7 stage II, 15 stage III and 9 stage IV. Immunohistochemical expression of VEGFR1 was studied through the technique of tissue-matrix using Tissue Arrayer Device (Beecher Instruments, Sun Prairie, WI), using the polyclonal antibody against VEGFR1 (Santa Cruz Biotechnology, California, USA). Results Positive VEGFR1 immunohistochemical expression was noted in 23 cases (59%). The number of positive tumours was not related with clinical stage but there was a different statistically significant association (p:0,0009) between VEGFR1 positivity and histological type, corresponding the greater percentages of positive results to adenocarcinomas (93,3%) versus in squamous cell carcinomas (37,5%). Likewise, SUV max values were higher (p: 0,039) in negative VEGFR1 carcinomas than in positive VEGFR1 tumors (r: 4-32,1; 16,4+/-6,4 (median 16,1) vs r: 3-47; 14,5+/-8,6 (12,8)). Conclusions Our results led us to consider that in NSCLC, the negative VEGFR1 immunohistochemical expression is associated significantly with squamous cell carcinomas subtype and with higher SUV max values in 18F-FDG-PET. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect